Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired…
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed…
EyeCare Partners Releases Inaugural Quality and Outcomes Report, Showcasing Impact and Industry-Leading Benchmarks
ST. LOUIS--(BUSINESS WIRE)--EyeCare Partners (ECP), the nation’s leading provider of clinically integrated…
